Recognizing and Managing Cancer-Associated Lambert-Eaton Myasthenic Syndrome - Episode 1
Clinical Presentation and Early Identification of Cancer-Associated LEMS
Panelists discuss how early segment-level recognition of CA-LEMS hinges on spotting hallmark clinical cues (proximal lower-extremity weakness, autonomic dysfunction, and reflexes that transiently improve after exercise) and not dismissing symptoms as deconditioning or cancer-treatment effects, given frequent links to SCLC and other malignancies.
In this opening segment, the expert faculty introduce the clinical context of cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) and outline the goals of the discussion, emphasizing the importance of early recognition and coordinated oncologic–neurologic care. They describe LEMS as a rare neurologic disorder, frequently linked to small cell lung cancer but also associated with other malignancies, including prostate cancer with neuroendocrine features. The panel highlights clinical features such as profound proximal lower-extremity weakness, autonomic dysfunction (including dry eyes, dry mouth, constipation, and erectile dysfunction), and the characteristic pattern of depressed reflexes that improve after brief exercise. They note the diagnostic challenges in oncology, where cancer treatments and general deconditioning can mask neuromuscular symptoms. The faculty also stress the significant impact of LEMS on mobility and daily functioning, underscoring the need for early neurological evaluation and timely initiation of available therapies.
Related Content:
